John R. Petersen, Ph.D.

John R. Petersen, Ph.D.

Professor of Pathology
Member of UTMB Cancer Center

University of Texas Medical Branch
5.156 John Sealy Annex
301 University Boulevard
Galveston, TX 77555-0551

Office: (409) 772-1350
Fax: (409) 772-9231
jrpeters@utmb.edu

« Back

John R. Petersen, Ph.D.

Professional Education

Degree Institution Field of Study Graduation Year
B.S. Colorado State University Chemistry 1970
M.S. Idaho State University Organic Chemistry 1927
Ph.D. Texas A&M University BioOrganic Chemistry 1976

Honors

  • Fellow of the National Academy of Clinical Biochemistry
  • Secretary of National Academy of Clinical Biochemistry
  • Treasure of the CPOCT Division of the American Association of Clinical Chemistry

Professional Affiliations

  • American Association of Clinical Chemistry
  • American Chemical Society
  • American Physiological Society

Research Interests

Chronic hepatitis C affects about 3 million adults in the United States. Current treatment is aimed at eliminating the virus to prevent progression and, hopefully, promote regression of hepatic fibrosis. Approximately half of the patients treated for hepatitis C fail to clear the virus. Presently the only proven method of assessing the effect of therapy on hepatic fibrosis is liver biopsy which is both invasive and expensive. In addition, it is also impractical to perform biopsies repeatedly on the same patient and biopsies may not accurately reflect what is occurring in the liver. Thus, most clinicians agree that serum markers would be very helpful in identifying patients at increased risk for fibrosis. As part of the initial investigation to identify potential markers we are using serum from patients with Hepatitis C with various stages of fibrosis and proteomics (mass spectrometry) to determine if differences in serum protein patterns exist. In conjunction with routine clinical laboratory results, markers identified by mass spectrometry could offer advantages in the assessment and management of patients with hepatitis C who are undergoing treatment or simply being followed in a clinic. We have recently extended this study to identify potential markers to identify patients that have early stage liver cancer (HCC). Preliminary results of ability of four markers to identify HCC in the presence of HCV have been promising.

Selected Publications

  1. Payne DA, Petersen JR. Rapid molecular testing for bioterrorism agents: Targets, Tactics and Technology. J. Clin. Ligand Assay 25:348-57; 2002.
  2. Chen J, Wang L, Chen JJ-Y, Sahu GK, Tyring S, Ramsey K, Indrikovs AJ, Petersen JR, Paar D, Cloyd MW. Detection of anti-HIV antibodies which recognize conformational epitopes of gp160 allows early diagnosis of HIV infection. J. Infect. Dis. 186:321-31; 2002.
  3. Mohammad AA, Elefano EC, Leigh D, Stredler D, Okorodudu AO, Petersen JR. Use of computer simulation to study the impact of increasing test volume on turn around times of STAT samples on ci8000 integrated chemistry and immunoassay analyzer. Clin. Chem. 50:1952-55; 2004.
  4. Petersen JR, Okorodudu AO, Mohammad AA, Fernando A, Shattuck KE. Association of transcutaneous bilirubin testing in hospital with decreased readmission rate for Hyperbilirubinemia. Clin. Chem. 51;540-44; 2005.
  5. Snyder N, Gajula L, Xiao S-Y, Grady J, Luxon B, Lau DTY, Soloway R, Petersen JR. APRI: A easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J. Clin. Gastroenterol. 40:535-42; 2006.
  6. Jabeen R, Mohammad AA, Elefano EC, Petersen JR, Saleemuddin S. Antibodies and Fab fragments protect Cu,Zn-SOD against methylglyoxal-induced inactivation. Biochim. Biophys. Acta 1760:1167-74; 2006.
  7. Jabeen R, Payne DA, Wiktorowicz J, Mohammad AA, Petersen JR. Capillary electrophoresis and the clinical laboratory. Electrophoresis 2006 Special Issue on Pharmaceutical analysis 27:2413-38; 2006.
  8. Jabeen R, Saleemuddin S, Petersen JR, Mohammad AA. Inactivation and modification of superoxide dismutase by glyoxal: Prevention by antibodies. Biochimie 89:311-18; 2007.
  9. Petersen JR, Finley JB, Mohammad AA, Okorodudu AO, Grady JJ, Bajaj M. Effect of Point of Care on the Maintenance of Glycemic Control as Measured by Hemoglobin A1c. Diabetes Care 30:713-15; 2007.
  10. Snyder N, Nguyen A, Gajula L, Soloway RD, Xiao S-Y, Lau DTY, Petersen JR. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin. Chim. Acta 381:119-123; 2007.
  11. Petersen JR, Finley JB, Mohammad AA, Okorodudu AO, Grady JJ, Bajaj M. How Point of Care Hemoglobin A1c Routinely Available in a Clinic Setting Affects Glycemic Control. Point Care J. 7:72-5; 2008.
  12. Petersen JR, Graves DF, Tacker DH, Okorodudu AO, Mohammad AA, Cardenas VJ. Comparison of POCT and central laboratory blood glucose results using arterial, capillary, and venous samples from MICU patients on a Tight Glycemic Protocol. Clin. Chim. Acta 396:10-13; 2008.
  13. Trang T, Petersen JR, Snyder N. Non-invasive markers of Hepatic Fibrosis in Patients Co-infected with HCV and HIV: Comparison of the APRI and FIB-4 INDEX. Clin. Chim. Acta 297:51-4; 2008.
  14. Omoruyi FO, Okorodudu AO, Mohammad AA, Petersen JR. Acute renal failure in the presence of chronic renal disease in a 31 year old Caucasian female. LabMedicine 39:533-35; 2008.
  15. Kasturi KS, Petersen JR. Point-of-Care Glycosylated Hemoglobin and its Impact on Diabetes Care. Pract Diabetology 27:20-24;2008.
  16. Snyder N, Petersen, J. The APRI and the RVR. J. Clin. Gastroenterol. 43:500-1; 2009.
  17. Omoruyi FO, Okorodudu AO, Mohammad AA, Petersen JR. Hepatorenal syndrome in a 52 year old. LabMedicine 40:274-76; 2009.
  18. El-Beshbishi E-B, Shattuck KE, Mohammad AA, Petersen JR. Hyperbilirubinemia and Transcutaneous Bilirubinometry. Clin Chem 55:1280-1287; 2009.

NIH Biosketch